Despite Strong Performance, Revised Outlook Drags Down Investor Sentiment

Quarterly Earnings Exceed Projections, But Future Outlook Dims

The global healthcare giant announced its quarterly financial outcomes, revealing sales of $11.16 billion, which surpassed the analyst consensus of $10.99 billion. Furthermore, Abbott's adjusted earnings reached $1.15 per share, outperforming both Wall Street's expectation of $1.14 and its own internal guidance of $1.12-$1.18 per share. The company experienced a 7.8% increase in sales on a reported basis, and a 3.7% rise on a comparable basis, factoring in the integration of Exact Sciences.

Medical Device and Diabetes Care Sectors Propel Growth

The medical devices division demonstrated significant strength, with sales climbing 13.2% on a reported basis to $5.54 billion, and 8.5% on a comparable basis. This expansion was largely fueled by double-digit growth across its Electrophysiology, Heart Failure, and Rhythm Management segments. Similarly, the Diabetes Care sector reported sales of approximately $2.08 billion, with continuous glucose monitor sales increasing by 14.2% on a reported basis and 7.6% on a comparable basis.

Diagnostics Face Challenges Amidst Mild Respiratory Season

The diagnostics division presented a more varied performance. Sales grew 6.1% on a reported basis to $2.18 billion, and 1.8% on a comparable basis. Core Laboratory Diagnostics, generating $1.27 billion, saw growth primarily in the U.S., Europe, and Latin America, with an increase in both year-over-year and sequential sales. However, Rapid and Molecular Diagnostics experienced reduced demand for respiratory virus tests due to a less severe respiratory virus season compared to the previous year. Additionally, Nutrition sales declined by 6% (-7.7% on a comparable basis) to $2.02 billion, attributed to lower sales volumes and strategic pricing adjustments in late 2025. Conversely, Established Pharmaceuticals sales surged 13.2% (+9% on a comparable basis), reaching $1.43 billion.

Revised Annual Guidance Impacts Investor Confidence

On Thursday, Abbott Laboratories announced an adjusted earnings forecast for the second quarter of 2026, ranging from $1.25-$1.31, which fell below the consensus estimate of $1.37. The company further revised its fiscal year 2026 adjusted earnings guidance downward, from an initial $5.55-$5.80 per share to $5.38-$5.58 per share, missing the Wall Street consensus of $5.62. This updated guidance includes a 20-cent per share dilution resulting from the acquisition of Exact Sciences. Despite this, the company projects fiscal 2026 comparable sales growth between 6.5% and 7.5%. Chairman and CEO Robert Ford stated during an investor call that the Exact Sciences acquisition is expected to add approximately $3 billion in incremental sales in 2026, thereby accelerating Abbott's long-term sales growth rate.

Abbott's Stock Reaches New Low

Following these announcements, Abbott Laboratories shares experienced a significant drop, falling 4.76% to $96.72. This downturn pushed the stock to a new 52-week low, according to market data.